News - Page 4
Organ-on-a-chip: the next generation tool for drug development?
Organ-on-a-chip (OoC) or Microphysiological systems (MPS) are microfluidic devices providing a controlled microenvironment for miniaturised tissues mimicking physiological architecture and function of human tissues and organs. The application of dynamic…
Read update
Retinal Organoids for Drug Discovery
Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…
Read update
Why is an in vitro model of the glomerulus desperately needed?
In most cases, once the kidney’s function is limited, the only treatment options are dialysis and kidney transplant. The absence of effective drugs to treat kidney disease is partly…
Read update
How to reduce drug attrition during drug development?
There are two main causes of drug attrition: safety and efficacy, and in both instances, the common denominator is the inadequacy of current preclinical models to predict outcomes in…
Read update
Dr Kathryn Garner, Head of Kidney Development at NB
As she narrates her story, you have the impression that you have made the journey with her, her words becoming rich images in…
Read update
iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery
What retinal models are available for drug development? Animal models are the most frequently used for investigating safety and efficacy of ophthalmic drugs. However, due to several key physiological differences,…
Read update
In vitro models for chronic kidney disease (CKD)
Phosphate balance is central to many metabolic pathways, and the kidneys play a key role in the reabsorption and excretion of phosphate to achieve this balance. In CKD, however,…
Read update
Thought Leadership Workshop hosted by NB: Emerging in vitro technologies for gene therapy applications
These include the first oligonucleotide-based therapies (Spinraza, Exondys, Vyondys), in vivo gene therapies (Luxturna and Zolgensma) and the first cell therapies (Kymriah, Yescarta, Tescartus). Such novel therapeutics treat disorders varying…
Read update
Lung epithelium in vitro modelling of SARS-CoV2 infections to aid Covid-19 treatments
Newcells Biotech’s team has developed a state-of-the-art iPSC-derived in vitro model of the human upper airway to accelerate the development of novel treatments against Covid-19 and other respiratory…
Read update
Global scientific expertise built into every NB product & service
At Newcells Biotech, we build our Industry leading scientific expertise and technical excellence into all the products and services we offer to our customers, delivering innovative solutions for drug…
Read update
NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study
Newcells Biotech and Takeda Pharmaceutical International Co. have collaborated in a study designed to assess drug safety. The study evaluated a set of 36 known drugs and…
Read update
Successful EU initiative adds a new 3D lung airway model to NB’s portfolio for drug safety testing
Newcells Biotech is collaborating with industry leaders and expert academics in a European-wide interdisciplinary initiative to develop animal-free methods for drug safety evaluations. The initiative (the EU funded
Read update
